These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

499 related items for PubMed ID: 27519561

  • 1. A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.
    Lai FH, Ng DS, Bakthavatsalam M, Chan VC, Young AL, Luk FO, Tsang CW, Brelén ME.
    Am J Ophthalmol; 2016 Oct; 170():91-99. PubMed ID: 27519561
    [Abstract] [Full Text] [Related]

  • 2. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Hashizume K, Mizota A, Yuzawa M.
    Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
    [Abstract] [Full Text] [Related]

  • 3. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
    Breukink MB, Mohr JK, Ossewaarde-van Norel A, den Hollander AI, Keunen JE, Hoyng CB, Boon CJ.
    Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
    [Abstract] [Full Text] [Related]

  • 4. Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).
    Lai TY, Wong RL, Chan WM.
    Trans Am Ophthalmol Soc; 2015 Mar; 113():T8. PubMed ID: 26755855
    [Abstract] [Full Text] [Related]

  • 5. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].
    Liu Y, Li L, Xu G, Wang W.
    Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704
    [Abstract] [Full Text] [Related]

  • 6. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
    Sheptulin V, Purtskhvanidze K, Roider J.
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
    [Abstract] [Full Text] [Related]

  • 7. Correlation of integrity of cone outer segment tips line with retinal sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K, Shinoda K, Imamura Y, Matsumoto CS, Mizutani Y, Mizota A, Yuzawa M.
    Am J Ophthalmol; 2012 Sep; 154(3):579-85. PubMed ID: 22818904
    [Abstract] [Full Text] [Related]

  • 8. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.
    Nicolò M, Zoli D, Musolino M, Traverso CE.
    Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224
    [Abstract] [Full Text] [Related]

  • 9. Half-dose Versus Half-time Photodynamic Therapy for Central Serous Chorioretinopathy.
    Liu HY, Yang CH, Yang CM, Ho TC, Lin CP, Hsieh YT.
    Am J Ophthalmol; 2016 Jul; 167():57-64. PubMed ID: 27084002
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Photodynamic therapy for steroid-associated central serous chorioretinopathy.
    Lee TG, Kim JE.
    Br J Ophthalmol; 2011 Apr; 95(4):518-23. PubMed ID: 20679080
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK, Chang CK, Peng CH.
    Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
    [Abstract] [Full Text] [Related]

  • 15. Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy.
    Shinojima A, Kawamura A, Mori R, Fujita K, Yuzawa M.
    Retina; 2011 Oct; 31(9):1912-20. PubMed ID: 21952105
    [Abstract] [Full Text] [Related]

  • 16. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial.
    Zhao M, Zhang F, Chen Y, Dai H, Qu J, Dong C, Kang X, Liu Y, Yang L, Li Y, Zhou P, Pan CT, Zhang L, Liu P, Zhou H, Jiao X, Xiong Y, Tian R, Lu Y, Yu X, Li X.
    JAMA Ophthalmol; 2015 Mar; 133(3):333-40. PubMed ID: 25555191
    [Abstract] [Full Text] [Related]

  • 17. [Photodynamic therapy for chronic central serous chorioretinopathy and diffuse retinal epitheliopathy].
    Cornut PL, Quaranta-El Maftouhi M, Mauget-Faÿsse M.
    J Fr Ophtalmol; 2012 Feb; 35(2):82-7. PubMed ID: 21889817
    [Abstract] [Full Text] [Related]

  • 18. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group.
    Roca JA, Wu L, Fromow-Guerra J, Rodríguez FJ, Berrocal MH, Rojas S, Lima LH, Gallego-Pinazo R, Chhablani J, Arevalo JF, Lozano-Rechy D, Serrano M.
    Br J Ophthalmol; 2018 Dec; 102(12):1696-1700. PubMed ID: 29439089
    [Abstract] [Full Text] [Related]

  • 19. Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results.
    Fujita K, Yuzawa M, Mori R.
    Retina; 2011 Apr; 31(4):772-8. PubMed ID: 20890236
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.